Breast cancer treatment and its impact on survival in Morocco: a study over a decade.
Breast cancer
Determinants
Disease-free survival
Management appropriateness
Morocco
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
19
01
2024
accepted:
27
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
epublish
Résumé
In Morocco, much progress has been made in breast cancer treatment. However, there is limited information on survival outcomes of breast cancer patients according to their therapeutic management. A pattern-of-care study was conducted in Morocco's two main oncology centres: Rabat and Casablanca and has shown that major progress has been made in the quality of care with survival rates comparable to those in developed countries. The present study focuses on the different therapeutic strategies used in breast cancer and their impact on prognosis. Patients were classified into two categories: those considered as appropriately managed and those who were not. A total of 1901 women with stage I to III breast cancer were included in this study, the majority (53%) were adequately managed and had better disease-free survival (DFS) rates than those who were not: DFS at 3 years (88% versus 62%) and at 5 years (80% versus 50%). Potential significant determinants of better management were: treatment in Rabat's oncology centre, treatment between 2008 and 2012, being aged younger than 60 years, and early TN stage. This study demonstrated the value of proper integrated and coordinated management in a comprehensive cancer centre, to improve breast cancer survival.
Sections du résumé
BACKGROUND
BACKGROUND
In Morocco, much progress has been made in breast cancer treatment. However, there is limited information on survival outcomes of breast cancer patients according to their therapeutic management.
METHODS
METHODS
A pattern-of-care study was conducted in Morocco's two main oncology centres: Rabat and Casablanca and has shown that major progress has been made in the quality of care with survival rates comparable to those in developed countries. The present study focuses on the different therapeutic strategies used in breast cancer and their impact on prognosis. Patients were classified into two categories: those considered as appropriately managed and those who were not.
RESULTS
RESULTS
A total of 1901 women with stage I to III breast cancer were included in this study, the majority (53%) were adequately managed and had better disease-free survival (DFS) rates than those who were not: DFS at 3 years (88% versus 62%) and at 5 years (80% versus 50%). Potential significant determinants of better management were: treatment in Rabat's oncology centre, treatment between 2008 and 2012, being aged younger than 60 years, and early TN stage.
CONCLUSION
CONCLUSIONS
This study demonstrated the value of proper integrated and coordinated management in a comprehensive cancer centre, to improve breast cancer survival.
Identifiants
pubmed: 38956536
doi: 10.1186/s12885-024-12570-6
pii: 10.1186/s12885-024-12570-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
786Informations de copyright
© 2024. The Author(s).
Références
Registre des Cancers de la Région du Grand Casablanca. – Rapport d’Incidence 2013–2017. April 2022. https://www.contrelecancer.ma/site_media/uploaded_files/Registre_des_Cancers_de_la_Region_du_Grand_Casablanca_2013-2017.pdf .
Littlejohns P. Trastuzumab for early breast cancer: evolution or revolution? Lancet Oncol. 2006;7:22–3. https://doi.org/10.1016/s1470-2045(05)70533-7 .
doi: 10.1016/s1470-2045(05)70533-7
pubmed: 16408378
Foulon A, Theret P, Rodat-Despoix L, Kischel P. Beyond chemotherapies: recent strategies in breast Cancer Treatment. Cancers (Basel). 2020;12:2634. https://doi.org/10.3390/cancers12092634 .
doi: 10.3390/cancers12092634
pubmed: 32947780
Selmouni F, Zidouh A, Belakhel L, et al. Tackling cancer burden in low-income and middle-income countries: Morocco as an exemplar. Lancet Oncol. 2018;19:e93e101. https://doi.org/10.1016/S1470-2045(17)30727-1 .
doi: 10.1016/S1470-2045(17)30727-1
Association Marocaine de Recherche et Formation en Oncologie Medicale. Guide des protocoles thérapeutiques en oncologie. Bulletin Marocain de l’Oncologie. 2021. http://amfrom.ma/assets/pdfs/Guide%20Th%C3%A9rapeutique.pdf .
Mrabti H, Sauvaget C, Benider A, et al. Patterns of care of breast cancer patients in Morocco - A study of variations in patient profile, tumour characteristics and standard of care over a decade. Breast. 2021;59:193–202. https://doi.org/10.1016/j.breast.2021.07.009 .
doi: 10.1016/j.breast.2021.07.009
pubmed: 34280610
pmcid: 8319441
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22:1736–47. https://doi.org/10.1093/annonc/mdr304 .
doi: 10.1093/annonc/mdr304
pubmed: 21709140
pmcid: 3144634
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206–23. https://doi.org/10.1093/annonc/mdt303 .
doi: 10.1093/annonc/mdt303
pubmed: 23917950
pmcid: 3755334
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast Cancer 2017. Ann Oncol. 2017;28:1700–12. https://doi.org/10.1093/annonc/mdx308 .
doi: 10.1093/annonc/mdx308
pubmed: 28838210
pmcid: 6246241
Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F, ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi7-23. https://doi.org/10.1093/annonc/mdt284 . Epub 2013 Aug 22. PMID: 23970019.
Mostafa A, Ghorbal B. Using WinBUGS to Cox model with changing from the baseline hazard function. Appl Math Sci. 2011;5:2217–40.
Ntzoufras L. Bayesian Modeling Using WinBUGS. Wiley Series in Computational Statistics, Published by John Wiley & Sons, Inc., Hoboken, New Jersey, 2009.
Ntzoufras L. Chapter 9: bayesian hierarchical models. Ntzoufras L. bayesian modeling using WinBUGS. Wiley Series in Computational Statistics. Hoboken, New Jersey: Published by John Wiley & Sons, Inc.; 2009. pp. 305–40.
doi: 10.1002/9780470434567.ch9
Mimouni M, Chaouki W, Errihani H, Benjaafar N. Analyse des délais de traitement du cancer du sein: expérience d’un centre de référence tertiaire au Maroc [An analysis of breast cancer treatment waiting times: experience of a tertiary referral center in Morocco]. Bull Cancer. 2018;105:755–62. https://doi.org/10.1016/j.bulcan.2018.05.010 .
doi: 10.1016/j.bulcan.2018.05.010
pubmed: 30005892
Bakkach J, Mansouri M, Derkaoui T, et al. Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco. BMC Womens Health. 2017;17:106. https://doi.org/10.1186/s12905-017-0456-1 .
doi: 10.1186/s12905-017-0456-1
pubmed: 29121898
pmcid: 5680801
Kurian AW, Bondarenko I, Jagsi R, et al. Recent trends in Chemotherapy Use and oncologists’ treatment recommendations for early-stage breast Cancer. J Natl Cancer Inst. 2018;110:493–500. https://doi.org/10.1093/jnci/djx239 .
doi: 10.1093/jnci/djx239
pubmed: 29237009
Slaoui M, Razine R, Ibrahimi A, Attaleb M, Mzibri ME, Amrani M. Breast cancer in Morocco: a literature review. Asian Pac J Cancer Prev. 2014;15:1067–74. https://doi.org/10.7314/apjcp.2014.15.3.1067 .
doi: 10.7314/apjcp.2014.15.3.1067
pubmed: 24606420
Khalil AI, Bendahhou K, Mestaghanmi H, Saile R, Benider A. Cancer Du Sein Au Maroc: profil phénotypique des tumeurs [Breast cancer in Morocco: phenotypic profile of tumors]. Pan Afr Med J. 2016;25:74. https://doi.org/10.11604/pamj.2016.25.74.9966 .
doi: 10.11604/pamj.2016.25.74.9966
pubmed: 28292037
pmcid: 5324149
Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. BMC Womens Health. 2017;17:3. https://doi.org/10.1186/s12905-016-0361-z .
doi: 10.1186/s12905-016-0361-z
pubmed: 28068979
pmcid: 5223366
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;2012(CD006243). https://doi.org/10.1002/14651858.CD006243 .
Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019;9:CD004421. https://doi.org/10.1002/14651858.CD004421 .
doi: 10.1002/14651858.CD004421
pubmed: 31476253
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. https://doi.org/10.1093/annonc/mdz173 .
doi: 10.1093/annonc/mdz173
pubmed: 31161190